Galera Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc. (ticker: GRTX) is a United States biopharmaceutical company that is currently quoted on the OTCQB market in the U.S.; it was formerly listed on the Nasdaq Global Market before being delisted in 2024. For French-speaking investors, that makes Galera a highly event-driven micro/small-cap healthcare name with elevated clinical, regulatory, financing, and transaction risk. The company is incorporated in Delaware and its operational headquarters is in Malvern, Pennsylvania, United States. Founded in 2012, Galera built its business around small-molecule superoxide dismutase (SOD) mimetics designed to improve radiotherapy outcomes in oncology. Its best-known historical program has been avasopasem manganese, previously referred to as GC4419, a candidate developed to reduce severe oral mucositis caused by radiotherapy. The company has also received important U.S. regulatory designations for that asset, including Fast Track and Breakthrough Therapy status, which for years supported the investment case. More recently, Galera expanded its asset base through the acquisition of Nova Pharmaceuticals in December 2024, and in April 2026 it announced a merger agreement with Obsidian Therapeutics. If completed, the combined company is expected to operate under the Obsidian Therapeutics name and shift primary strategic emphasis toward Obsidian’s engineered tumor infiltrating lymphocyte (TIL) cell therapy platform for solid tumors, while continuing to support Galera’s pipeline. From a competitive standpoint, Galera operates in a difficult and crowded corner of oncology, where value creation depends less on current revenues and more on clinical readouts, regulatory progress, and capital-market access. It does not have a broad commercial franchise or a diversified geographic footprint; its core development activity is largely U.S.-based. That means the company’s positioning is best understood as that of a specialized clinical-stage developer rather than a commercial pharmaceutical platform. For investors, the most relevant variables are trial outcomes, partnering and merger execution, and liquidity runway rather than traditional top-line growth metrics. Recent developments have been material. Galera was delisted from Nasdaq in 2024 and now trades OTCQB under GRTX. It completed the Nova Pharmaceuticals acquisition at the end of 2024. In April 2026, it entered into a merger agreement with Obsidian Therapeutics, a transaction that could materially alter the company’s strategic identity, pipeline mix, and future listing profile. Overall, Galera remains a high-risk biotechnology situation, with its equity story driven primarily by corporate actions and clinical catalysts rather than by operating fundamentals.